Structural and Stereoelectronic Requirements for the Inhibition of Mammalian 2,3-Oxidosqualene Cyclase by Substituted Isoquinoline Derivatives
- 1 January 1996
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 39 (12) , 2302-2312
- https://doi.org/10.1021/jm9504621
Abstract
2,3-Oxidosqualene lanosterol-cyclase (OSC; EC 5.4.99.7) is an attractive target for the design of compounds that block hepatic cholesterol biosynthesis. (4aα,5α,6β,8aβ)-Decahydro-5,8a-dimethyl-2-(1,5,9-trimethyldecyl)-6-isoquinolinol (1) and simplified analogs have been devised to inhibit this enzyme by mimicking the postulated pro-C-8 high-energy intermediary carbocation occurring during the cyclization−rearrangement pathway. In order to gain an understanding into the mechanism by which these types of molecules inhibit OSC, we have synthesized a series of substituted isoquinoline derivatives 3 and investigated the structural and stereoelectronic requirements, and their stringency, that make 3 potential high-energy intermediate analogs of OSC. Determination of the IC50 values of the different compounds, with rat liver microsomal cyclase, allowed the study of the relative importance of (i) the nature and the stereochemistry of the nitrogen side chain, (ii) the presence of methyl groups at C-5 and C-8a (ring junction), (iii) the presence and stereochemistry of the C-6 hydroxyl group, (iv) the nature of the ring junction, and (v) the absolute configuration of the bicyclic system. The resulting structure−activity relationships seem to validate the mechanism of action of these inhibitors as analogs of a pro-C-8 high-energy intermediate and delineate the minimal requirements for the design of efficient isoquinoline-based, or simplified, OSC inhibitors.Keywords
This publication has 40 references indexed in Scilit:
- Preferential cyclization of 2,3(S):22(S),23-dioxidosqualene by mammalian 2,3-oxidosqualene-lanosterol cyclaseBiochemical and Biophysical Research Communications, 1992
- Regulation of the mevalonate pathwayNature, 1990
- Lovastatin and Simvastatin - Inhibitors of HMG CoA Reductase and Cholesterol BiosynthesisCardiology, 1990
- Potent inhibition of cholesterol biosynthesis in 3T3 fibroblasts by N-[(1,5,9)-trimethyldecyl]-4α, 10-dimethyl-8-AZA-trans-decal-3β-OL, a new 2,3-oxidosqualene cyclase inhibitorBiochemical Pharmacology, 1988
- Inhibition of cholesterol biosynthesis in 3T3 fibroblasts by 2-AZA-2,3-dihydrosqualene, a rationally designed 2,3-oxidosqualene cyclase inhibitorBiochemical Pharmacology, 1986
- 24,25-Epoxysterol metabolism in cultured mammalian cells and repression of 3-hydroxy-3-methylglutaryl-CoA reductase.Published by Elsevier ,1986
- Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductaseJournal of Medicinal Chemistry, 1985
- Effects of 3.beta.-[2-(diethylamino)ethoxy]androst-5-en-17-one on the synthesis of cholesterol and ubiquinone in rat intestinal epithelial cell culturesBiochemistry, 1983
- Bioorganic chemistry. Total synthesis of tetra- and pentacyclic triterpenoidsAccounts of Chemical Research, 1975
- Zur Kenntnis der Triterpene. 190. Mitteilung. Eine stereochemische Interpretation der biogenetischen Isoprenregel bei den TriterpenenHelvetica Chimica Acta, 1955